[go: up one dir, main page]

BRPI0509067A - formulações de matriz oral que compreendem licarbazepina - Google Patents

formulações de matriz oral que compreendem licarbazepina

Info

Publication number
BRPI0509067A
BRPI0509067A BRPI0509067-9A BRPI0509067A BRPI0509067A BR PI0509067 A BRPI0509067 A BR PI0509067A BR PI0509067 A BRPI0509067 A BR PI0509067A BR PI0509067 A BRPI0509067 A BR PI0509067A
Authority
BR
Brazil
Prior art keywords
licarbazepine
matrix formulations
oral matrix
oral
licarbazepin
Prior art date
Application number
BRPI0509067-9A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0509067A publication Critical patent/BRPI0509067A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

FORMULAçõES DE MATRIZ ORAL QUE COMPREENDEM LICARBAZEPINA. A presente invenção refere-se a composições farmacêuticas que compreendem 10,11-diidro-10-hidróxi-5H-dibenz¢b,f!azepina-5-carboxamida (também referido como "licarbazepina") como substância de fármaco.
BRPI0509067-9A 2004-03-22 2005-03-21 formulações de matriz oral que compreendem licarbazepina BRPI0509067A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds
PCT/EP2005/002988 WO2005092294A1 (en) 2004-03-22 2005-03-21 Oral matrix formulations comprising licarbazepine

Publications (1)

Publication Number Publication Date
BRPI0509067A true BRPI0509067A (pt) 2007-08-21

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509067-9A BRPI0509067A (pt) 2004-03-22 2005-03-21 formulações de matriz oral que compreendem licarbazepina

Country Status (16)

Country Link
US (1) US20070196488A1 (pt)
EP (1) EP1732519A1 (pt)
JP (1) JP2007529564A (pt)
AR (1) AR048318A1 (pt)
AU (1) AU2005226910B2 (pt)
BR (1) BRPI0509067A (pt)
CA (1) CA2558787A1 (pt)
EC (1) ECSP066860A (pt)
IL (1) IL177826A0 (pt)
MA (1) MA28527B1 (pt)
MX (1) MXPA06010810A (pt)
NO (1) NO20064808L (pt)
PE (1) PE20051156A1 (pt)
RU (1) RU2006137330A (pt)
TW (1) TW200534844A (pt)
WO (1) WO2005092294A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
ES2534560T3 (es) * 2005-05-06 2015-04-24 Bial-Portela & Ca, S.A. Acetato de eslicarbazepina y su uso
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
EP2683691B1 (en) 2011-03-08 2018-06-06 Jubilant Life Sciences Limited PROCESS FOR THE PREPARATION OF (S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE AND ESTERS THEREOF BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
EP3957302A1 (en) 2015-12-18 2022-02-23 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
PL374778A1 (en) * 2002-05-31 2005-10-31 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
US7465723B2 (en) * 2002-08-06 2008-12-16 Novartis Use of carboxamides for the treatment of tinnitus
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Also Published As

Publication number Publication date
MA28527B1 (fr) 2007-04-03
CA2558787A1 (en) 2005-10-06
ECSP066860A (es) 2006-11-24
WO2005092294A1 (en) 2005-10-06
JP2007529564A (ja) 2007-10-25
US20070196488A1 (en) 2007-08-23
NO20064808L (no) 2006-12-15
RU2006137330A (ru) 2008-05-10
AR048318A1 (es) 2006-04-19
AU2005226910A1 (en) 2005-10-06
IL177826A0 (en) 2006-12-31
PE20051156A1 (es) 2006-02-13
TW200534844A (en) 2005-11-01
EP1732519A1 (en) 2006-12-20
MXPA06010810A (es) 2006-12-15
AU2005226910B2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0015188A (pt) Composições farmacêuticas
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
IL173571A0 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
BRPI0620229A8 (pt) formulação
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
BR0308201A (pt) Derivados de quinolina
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
TNSN06298A1 (en) Disintegrating tablets comprising licarbazepine
BRPI0500420A (pt) composição estável para substáncia farmacologicamente ativa
DE602006002328D1 (de) Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
ECSP045039A (es) Composiciones de disgregación intraoral organolepticamente aceptables
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
TR200805337A2 (tr) Valsartan etkin maddesini içeren yeni oral farmasötik formülasyonlar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.